Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
Phase 2
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06933914
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences), Tianjin, Tianjin, China
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
Phase 3
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 20
- Registration Number
- NCT06932471
- Locations
- 🇨🇳
Peking Union Medical College Hospital (PUMCH)., Beijing, Beijing, China
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
Phase 3
Recruiting
- Conditions
- Paroxysmal Nocturnal Haemoglobinuria (PNH)
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT06932744
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Chinese Academy of Medical Sciences Hematology Hospital, Tianjin, Tianjin, China
QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study
Phase 2
Completed
- Conditions
- Cough
- Interventions
- Drug: QR052107B 100 mgDrug: QR052107B 400 mgDrug: Placebo
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 270
- Registration Number
- NCT06920836
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Phase 3
Not yet recruiting
- Conditions
- Essential Hypertension
- Interventions
- Drug: QR12000 75mgDrug: QR12000 75mg placeboDrug: QR12000 150mg placeboDrug: QR12000 150mg
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 810
- Registration Number
- NCT06716970
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Phase 2
Not yet recruiting
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Drug: MY008211A tabletsDrug: MY008211A tablets matched placebo
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06687174
To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects
Phase 1
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: MY008211A tabletsDrug: Placebo
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06543459
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Not yet recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06134414
A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 2
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06050226
- Locations
- 🇨🇳
Nstitute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin, China
Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: MY008211A tablets
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05828485
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
© Copyright 2025. All Rights Reserved by MedPath